Moreover, while our results show that mutant KRAS is sufficient to activate a high ISG signature that is seen across many human cancers, additional experiments (e.g., CRISPR) that correct mutations in KRAS would reveal whether oncogenic RAS signaling is necessary for high ISG expression in tumor cells. This evidence concerns the gene KRAS and cancer.